Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms
1 Pogledi
administrator
07/29/23
Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.
Prikaži više
Komentari na Facebooku
Nema komentara